168 related articles for article (PubMed ID: 10952769)
1. Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general.
Boxenbaum H
J Pharm Pharm Sci; 1999; 2(2):47-52. PubMed ID: 10952769
[TBL] [Abstract][Full Text] [Related]
2. Human in vivo competitive inhibition of P450 substrates: increased plasma concentrations as a function of hepatic extraction ratio and percent inhibition.
Boxenbaum H
J Pharm Pharm Sci; 1999; 2(3):89-91. PubMed ID: 10953254
[TBL] [Abstract][Full Text] [Related]
3. Effect of selected antimalarial drugs and inhibitors of cytochrome P-450 3A4 on halofantrine metabolism by human liver microsomes.
Baune B; Furlan V; Taburet AM; Farinotti R
Drug Metab Dispos; 1999 May; 27(5):565-8. PubMed ID: 10220483
[TBL] [Abstract][Full Text] [Related]
4. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole.
von Moltke LL; Greenblatt DJ; Harmatz JS; Duan SX; Harrel LM; Cotreau-Bibbo MM; Pritchard GA; Wright CE; Shader RI
J Pharmacol Exp Ther; 1996 Feb; 276(2):370-9. PubMed ID: 8632299
[TBL] [Abstract][Full Text] [Related]
5. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences.
Greenblatt DJ; Wright CE; von Moltke LL; Harmatz JS; Ehrenberg BL; Harrel LM; Corbett K; Counihan M; Tobias S; Shader RI
Clin Pharmacol Ther; 1998 Sep; 64(3):237-47. PubMed ID: 9757147
[TBL] [Abstract][Full Text] [Related]
6. Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole.
Lu C; Hatsis P; Berg C; Lee FW; Balani SK
Drug Metab Dispos; 2008 Jul; 36(7):1255-60. PubMed ID: 18381489
[TBL] [Abstract][Full Text] [Related]
7. Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships.
Ervine CM; Matthew DE; Brennan B; Houston JB
Drug Metab Dispos; 1996 Feb; 24(2):211-5. PubMed ID: 8742233
[TBL] [Abstract][Full Text] [Related]
8. A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data.
Lu C; Miwa GT; Prakash SR; Gan LS; Balani SK
Drug Metab Dispos; 2007 Jan; 35(1):79-85. PubMed ID: 17020957
[TBL] [Abstract][Full Text] [Related]
9. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
10. Current cytochrome P450 phenotyping methods applied to metabolic drug-drug interaction prediction in dogs.
Mills BM; Zaya MJ; Walters RR; Feenstra KL; White JA; Gagne J; Locuson CW
Drug Metab Dispos; 2010 Mar; 38(3):396-404. PubMed ID: 20007294
[TBL] [Abstract][Full Text] [Related]
11. Multiple oral dosing of ketoconazole influences pharmacokinetics of quinidine after intravenous and oral administration in beagle dogs.
Kuroha M; Shirai Y; Shimoda M
J Vet Pharmacol Ther; 2004 Oct; 27(5):355-9. PubMed ID: 15500574
[TBL] [Abstract][Full Text] [Related]
12. Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans.
Herman BD; Fleishaker JC; Brown MT
Clin Pharmacol Ther; 1999 Oct; 66(4):374-9. PubMed ID: 10546921
[TBL] [Abstract][Full Text] [Related]
13. Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist.
Lu C; Balani SK; Qian MG; Prakash SR; Ducray PS; von Moltke LL
J Pharmacol Exp Ther; 2010 Feb; 332(2):562-8. PubMed ID: 19889796
[TBL] [Abstract][Full Text] [Related]
14. Ketoconazole potentiates terfenadine-induced apoptosis in human Hep G2 cells through inhibition of cytochrome p450 3A4 activity.
Wang YJ; Yu CF; Chen LC; Chen CH; Lin JK; Liang YC; Lin CH; Lin SY; Chen CF; Ho YS
J Cell Biochem; 2002; 87(2):147-59. PubMed ID: 12244568
[TBL] [Abstract][Full Text] [Related]
15. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect.
Varis T; Kivistö KT; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 2000 Nov; 68(5):487-94. PubMed ID: 11103751
[TBL] [Abstract][Full Text] [Related]
16. Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey.
Ward KW; Stelman GJ; Morgan JA; Zeigler KS; Azzarano LM; Kehler JR; McSurdy-Freed JE; Proksch JW; Smith BR
Drug Metab Dispos; 2004 Feb; 32(2):172-7. PubMed ID: 14744938
[TBL] [Abstract][Full Text] [Related]
17. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions.
Obach RS; Walsky RL; Venkatakrishnan K; Gaman EA; Houston JB; Tremaine LM
J Pharmacol Exp Ther; 2006 Jan; 316(1):336-48. PubMed ID: 16192315
[TBL] [Abstract][Full Text] [Related]
18. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine.
Gomez DY; Wacher VJ; Tomlanovich SJ; Hebert MF; Benet LZ
Clin Pharmacol Ther; 1995 Jul; 58(1):15-9. PubMed ID: 7628178
[TBL] [Abstract][Full Text] [Related]
19. Determination of the enzyme(s) involved in the metabolism of amiodarone in liver and intestine of rat: the contribution of cytochrome P450 3A isoforms.
Shayeganpour A; El-Kadi AO; Brocks DR
Drug Metab Dispos; 2006 Jan; 34(1):43-50. PubMed ID: 16204463
[TBL] [Abstract][Full Text] [Related]
20. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
